Index Ventures has launched yet another venture fund. The firm says its newest fund, Index Ventures V, will be equipped with €350 million ($440 million) for early stage and seed investments in the technology, biotech and clean tech sectors across Europe, the U.S. and Israel. The funds were raised almost entirely from current investment partners, according to the company.
This is the fifth early stage fund the firm has launched in the past ten years and "reinforces the firm's commitment to investing in innovative and disruptive companies," the company said in a statement.
"On the biotech side, Index is focused on finding the best companies with the strongest pipelines," said Index partner Francesco De Rubertis. "We are equally interested in very early stage ventures and more mature companies with established proof-of-concept. In terms of therapeutic areas, our priorities are oncology, CNS, immunology and inflammation. We continue to see tremendous innovation and development within these areas, driven in part by the ever growing pharmaceutical pipeline deficit."
- check out the release